Literature DB >> 18577464

PGE2 and LTB4 tissue levels in benign and cancerous prostates.

Stéphane Larré1, Nguyen Tran, Cheng Fan, Hikmat Hamadeh, Jaqueline Champigneulles, Rahmène Azzouzi, Olivier Cussenot, Philippe Mangin, Jean Luc Olivier.   

Abstract

PGE2 and LTB4 are involved in inflammation and carcinogenesis in several tissues but have not been studied in prostate cancer and hyperplasia until now. We therefore measured PGE2 and LTB4 productions in a total of 206 prostate tissues from 116 patients including benign hyperplastic (90), pericancerous (106) and cancerous samples (10). We also analysed the influence of inflammation levels, prostate volume and glandular to epithelial ratio. PGE2 and LTB4 concentrations were measured using specific enzyme immunoassay kits. There was a correlation between PGE2 level, prostatic volume, inflammation score, and decreased glandular surface. By contrast, there was no correlation between LTB4 levels and inflammation or PGE2 production. Cancerous samples had higher LTB4 levels than pericancerous samples, but there was no difference in PGE2 levels. PGE2 and inflammation may be associated to stromal benign prostatic hyperplasia whereas LTB4 may play a role in prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18577464     DOI: 10.1016/j.prostaglandins.2008.05.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  19 in total

1.  Changes in the fatty acid composition of thymic and solid ehrlich carcinoma cells in mice under exposure to extremely high frequency electromagnetic radiation.

Authors:  T P Kulagina; A V Aripovsky; A B Gapeyev; N K Chemeris
Journal:  Dokl Biochem Biophys       Date:  2011-09-18       Impact factor: 0.788

2.  Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.

Authors:  D Altavilla; L Minutoli; F Polito; N Irrera; S Arena; C Magno; M Rinaldi; B P Burnett; F Squadrito; A Bitto
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells.

Authors:  Lin Miao; Jiandang Shi; Chun-Yu Wang; Yan Zhu; Xiaoling Du; Hongli Jiao; Zengnan Mo; Helmut Klocker; Chung Lee; Ju Zhang
Journal:  Mol Endocrinol       Date:  2010-03-29

Review 4.  Regulation of inflammation in cancer by eicosanoids.

Authors:  Emily R Greene; Sui Huang; Charles N Serhan; Dipak Panigrahy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-16       Impact factor: 3.072

5.  Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH).

Authors:  Irene Paterniti; Michela Campolo; Marika Cordaro; Rosalba Siracusa; Antonio Filippone; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Inflamm Res       Date:  2018-04-20       Impact factor: 4.575

Review 6.  Eicosanoids and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

7.  Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells.

Authors:  Jin-Wook Lee; Jae-Hong Kim
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

8.  A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells.

Authors:  H Kim; G-S Park; J E Lee; J-H Kim
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 7.640

9.  Targeting 20-HETE producing enzymes in cancer - rationale, pharmacology, and clinical potential.

Authors:  Anna Alexanian; Andrey Sorokin
Journal:  Onco Targets Ther       Date:  2013-03-26       Impact factor: 4.147

Review 10.  Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence.

Authors:  Karsten H Weylandt; Simona Serini; Yong Q Chen; Hui-Min Su; Kyu Lim; Achille Cittadini; Gabriella Calviello
Journal:  Biomed Res Int       Date:  2015-08-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.